Protocol Number: 08-CH-0213

Title:

WAGR Syndrome and Other 11p Contiguous Gene Deletions: Clinical Characterization and Correlation with Genotype

Number:

08-CH-0213

Summary:

This study will explore conditions caused by the absence of certain genes on chromosome 11. These conditions include WAGR syndrome, which is characterized by a kidney tumor called Wilm's tumor, aniridia (absence of the iris of the eye), genital and urinary abnormalities, mental retardation, and possibly other symptoms. This study will examine how the genes on chromosome 11 affect people and whether the absence of specific genes is associated with specific symptoms.

Healthy normal volunteers, people with isolated aniridia, and people with WAGR or another chromosome 11 gene deletion may be eligible for this study. Participants must be at least 6 years old. Parents of patients may also participate for genetic studies.

Participants undergo some or all of the following procedures, depending on whether they are a child, adult, healthy volunteer or parent of a patient:

- Medical history and physical examination, eye examination, blood, urine and saliva tests, electrocardiogram (EKG) and electroencephalogram (EEG)

- X-rays, scans and other tests to measure body composition (fat, muscle and bone development and thickness) and MRI to examine the eyes and the brain and to measure abdominal fat

- Ultrasound studies of the kidneys, ovaries and uterus (in females) and testes (in males)

- Meal tests, food diaries and food preference tests

- Questionnaires about eating and sleep habits, personality and character traits and responses to pain and injury

- Neuropsychological tests

-Tests of resting metabolic rate, energy expenditure and glucose (sugar) tolerance

- Hot and cold sensitivity tests, vibration sensitivity test, cold tolerance test and smell identification test

- Eye and hearing tests

- Nerve conduction studies and study of sensory information conduction from peripheral nerves to the spinal cord and brain

- Computer photography

- Evaluation by sub-specialists (e.g., endocrinologist, ophthalmologist, physiatrist, neurologist or others) as indicated by the patient's medical history and test results

Sponsoring Institute:

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA:

For WAGR/11p Deletion Subjects:

- Diagnosis of WAGR/11p deletion confirmed by prior genetic testing or clinical history consistent with WAGR syndrome (Wilms Tumor and/or genitourinary anomalies plus aniridia). Genetic diagnosis will be confirmed at the NIH, if not done previously

- Age greater than or equal to 6 years old (older age required in order to perform planned testing)

- Medically stable (so that the patient can safely undergo planned testing); if history of Wilms tumor, must be greater than 6 months since completion of chemotherapy and must be considered in remission by primary oncologist caring for the patient

For Parents of WAGR/11p Deletion Subjects:

- Biological parent of child with WAGR/11p deletion able to give consent for self participation.

For Healthy Control Subjects:

- Age greater than or equal to 6 years old

- No chronic medications. Use of as-needed and over-the-counter medications will be reviewed on a case-by-case basis by the Principal Investigator

- No chronic medical or psychiatric conditions anticipated to affect results or impede study participation

For Aniridia Subjects:

- Diagnosis of aniridia confirmed by ophthalmologist

- Age greater than or equal to 6 years old

- Medically stable, with no chronic medical or psychiatric conditions anticipated to affect results or impede study participation

EXCLUSION CRITERIA:

For WAGR/11p Deletion Subjects:

- Anorexiant use in preceding 6 months

- Greater than 2 percent body weight loss in preceding 6 months

- Pregnancy

- Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study

For Parents of WAGR/11p Deletion Subjects:

- No exclusions other than lack of ability to give consent for participation

For Healthy Control Subjects:

- Anorexiant use in preceding 6 months

- Greater than 2 percent body weight loss in preceding 6 months

- Pregnancy

- Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study

For Aniridia Subjects:

- Anorexiant use in preceding 6 months

- Greater than 2 percent body weight loss in preceding 6 months

- Pregnancy

- Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study

Special Instructions:

Currently Not Provided

Keywords:

Genotype/Phenotype Correlation

Energy Homeostasis

Nociception

Obesity

Behavior and Neurocognition

Recruitment Keyword(s):

WAGR Syndrome

Wilm's Tumor

Aniridia

Mental Retardation

Urogenital Abnormalities

Healthy Volunteer

Condition(s):

WAGR Syndrome

Wilm's Tumor

Aniridia

Urogenital Abnormalities

Mental Retardation

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Institute of Child Health and Human Development

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, Ritchey ML, Green DM, Nichols KE; National Wilms Tumor Study Group. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2003 Dec 15;21(24):4579-85.

Fischbach BV, Trout KL, Lewis J, Luis CA, Sika M. WAGR syndrome: a clinical review of 54 cases. Pediatrics. 2005 Oct;116(4):984-8.

Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics. 2007 Sep;90(3):397-406.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Clinical Research Informatics, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 01/30/2009